This is the text extract for Notification of Silver sulphadiazine (Flamazine) funding, browse documents here.

15 December 2009

Silver sulphadiazine (Flamazine) funding approved

PHARMAC is pleased to announce the approval of a supply agreement with Smith and Nephew Limited for silver sulphadiazine 1% cream (Flamazine). Smith and Nephew is discontinuing silver sulphadiazine 1% with 0.2% chlorhexidine digluconate (Silvazine) once its remaining stock is depleted (which has nearly occurred). The listing of Flamazine will ensure that a funded topical antibacterial, used primarily as a topical burn cream on second and third-degree burns, remains available.

Summary of the decision

Flamazine will be fully funded and listed in Section B and Section H of the Pharmaceutical Schedule from 1 January 2010 at a subsidy and price of $12.30 per 50 g OP (ex-manufacturer, excluding GST). Flamazine will also be available on PSO for up to 250 g (five tubes). We note that we had consulted on Flamazine having delisting protection until 1 January 2012; please note that Flamazine will not have delisting protection, and will now be subject to a risk sharing arrangement and a price and subsidy review in 2010. If you have any queries about this funding decision you can call our toll free number (9 am to 5 pm, Monday to Friday) on 0800 66 00 50.

Feedback received

We appreciate the feedback we received in response to consultation and acknowledge the time people took to respond. Responses were supportive towards the continued listing of a topical antibacterial for burns treatment on the Pharmaceutical Schedule.

A320655 - T09-357

1 of 1